REG - CRISM Therapeutics - AGM Statement

CRISM TherapeuticsAnnouncement

26/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250826:nRSZ4927Wa&default-theme=true

RNS Number : 4927W  CRISM Therapeutics Corporation  26 August 2025

 

26 August 2025

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

 

AGM Statement

 

CRISM Therapeutics (AIM: CRTX), the innovative UK drug delivery company
focused on the localised delivery of chemotherapy drugs, is holding its Annual
General Meeting ("AGM") today at 11am at the office of Fieldfisher LLP.  At
the meeting, CRISM's Non-Executive Chair, Dr Nermeen Varawalla will make the
following statement:

 

"This meeting marks our first AGM since CRISM Therapeutics was admitted to AIM
following the reverse takeover of Amur Minerals in May 2024. This
transformative transaction has provided us with the platform to deliver the
significant progress we have made since becoming a listed entity.  Our
strategy has delivered some key operational achievements during 2025.

 

"In June we successfully submitted our Clinical Trial Authorisation
application to the MHRA for our registration grade Phase 2 study of irinotecan
ChemoSeed in patients with resectable glioblastoma, a critical milestone in
the technology's development.  We recently announced the initiation of
production of a clinical batch of ChemoSeed under Good Manufacturing Practice
with ProMed Pharma.  Our progress is being supported by a recent fundraise,
raising £874,021 in June and I thank all shareholders for their continued
support.

 

"The potential of ChemoSeed extends beyond a single application and was
validated by a grant award from Innovate UK in March to support the
pre-clinical development of ChemoSeed for prostate cancer, representing a
second indication and significant market opportunity for our technology.

 

"In order to achieve our objectives, we must attract, retain and incentivise
the best people. To that end, we have established an Enterprise Management
Incentives Option Plan, to ensure our team is motivated and aligned with our
long-term goals, which shareholders are voting on today.

 

"Going forward we are focused on gaining trial approval from the MHRA in
glioblastoma and progressing towards dosing our first patients in early 2026.
 Additionally, we will continue to seek further validation for our novel
delivery method and are confident that ChemoSeed has the potential to
transform treatment for patients with solid-tumour cancers."

 

-Ends-

 

 

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Vadim Alexandre                   CRISM@buchanancomms.co.uk

                                 Adam Cowl
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

 

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

The Company's LEI is 213800XFW6MKVCHHPW88.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMUUSSRVRUWUAR